Skip to main content

Table 2 Resistance pattern of ESBL, MBL and AmpC producing isolates

From: Community acquired multi-drug resistant clinical isolates of Escherichia coli in a tertiary care center of Nepal

Antibiotics ESBL (n = 48) MBL (n = 30) Amp C (n = 18)
  No. of resistant isolates (%) No. of resistant isolates (%) No. of resistant isolates (%)
Ampicillin 44 (91.7) 24 (80.0) 18 (100)
Ampicillin-sulbactam 44 (91.7) 24 (80.0) 18 (100)
Cefazolin 48 (100) 28 (93.3) 16 (88.9)
Ceftazidime 48 (100) 30 (100) 18 (100)
Ceftriaxone 48 (100) 24 (80.0) 12 (66.7)
Cefepime 36 (75.0) 16 (53.3) 0 (0)
Cefoxitin 34 (70.8) 26 (86.7) 18 (100)
Piperacillin-tazobactam 22 (45.8) 18 (60.0) 12 (66.7)
Ticarcillin-clavulanic acid 44 (91.7) 22 (73.3) 16 (88.9)
Amoxicillin-clavulanic acid 48 (100) 30 (80.0) 18 (100)
Aztreonam 48 (100) 22 (73.3) 12 (66.7)
Imipenem 2 (4.2) 14 (46.7) 4 (22.2)
Meropenem 32 (66.7) 22 (73.3) 12 (66.7)
Gentamicin 14 (29.2) 18 (60.0) 6 (33.3)
Amikacin 2 (4.2) 16 (53.3) 4 (22.2)
Tobramicin 16 (33.3) 16 (53.3) 6 (33.3)
Ciprofloxacin 46 (95.8) 28 (93.3) 18 (100)
Ofloxacin 40 (83.3) 24 (80.0) 14 (77.8)
Cotrimoxazole 40 (83.3) 24 (80.0) 12 (66.7)
Chloramphenicol 6 (12.5) 14 (46.7) 4 (22.2)
Colistin 0 (0) 0 (0) 0 (0)